FDMT vs. STOK, ABCL, IMCR, VCEL, JANX, EWTX, RCUS, HRMY, AUPH, and PAHC
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Stoke Therapeutics (STOK), AbCellera Biologics (ABCL), Immunocore (IMCR), Vericel (VCEL), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Arcus Biosciences (RCUS), Harmony Biosciences (HRMY), Aurinia Pharmaceuticals (AUPH), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.
4D Molecular Therapeutics vs. Its Competitors
Stoke Therapeutics (NASDAQ:STOK) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.
In the previous week, 4D Molecular Therapeutics had 7 more articles in the media than Stoke Therapeutics. MarketBeat recorded 13 mentions for 4D Molecular Therapeutics and 6 mentions for Stoke Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.58 beat Stoke Therapeutics' score of 0.37 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.
Stoke Therapeutics has a net margin of 26.25% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. Stoke Therapeutics' return on equity of 18.32% beat 4D Molecular Therapeutics' return on equity.
Stoke Therapeutics has higher revenue and earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. 9.5% of Stoke Therapeutics shares are held by insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Stoke Therapeutics presently has a consensus price target of $30.83, suggesting a potential downside of 11.09%. 4D Molecular Therapeutics has a consensus price target of $29.50, suggesting a potential upside of 162.46%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Stoke Therapeutics.
Stoke Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the S&P 500.
Summary
Stoke Therapeutics beats 4D Molecular Therapeutics on 9 of the 17 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FDMT) was last updated on 10/21/2025 by MarketBeat.com Staff
